Related Experiment Videos
Exhaled nitric oxide in sarcoidosis.
M L Wilsher1, W Fergusson, D Milne
1Green Lane Respiratory Services, Auckland City Hospital, Auckland 1, New Zealand. mwilsher@adhb.govt.nz
Thorax
|October 26, 2005
Summary
Exhaled nitric oxide (NO) levels are not elevated in pulmonary sarcoidosis patients. This study found no significant difference in NO levels compared to healthy individuals, suggesting NO is not a reliable biomarker for this condition.
Area of Science:
- Pulmonary Medicine
- Immunology
- Respiratory Physiology
Background:
- Nitric oxide (NO) production in the lower respiratory tract indicates airway inflammation in conditions like asthma.
- NO modulates the immune system by inhibiting pro-inflammatory cytokines.
- Sarcoidosis involves granulomatous airway inflammation, prompting investigation into NO's role.
Purpose of the Study:
- To investigate if exhaled nitric oxide (NO) levels are elevated in pulmonary sarcoidosis.
- To determine if exhaled NO correlates with disease extent and severity in sarcoidosis.
Main Methods:
- Recruited 52 patients diagnosed with sarcoidosis.
- Performed thin-section computed tomography (CT) and pulmonary function tests.
- Measured exhaled nitric oxide (NO) levels in patients and 44 control subjects.
Main Results:
- Exhaled NO levels in sarcoidosis patients (median 6.8 ppb) were not significantly different from controls.
- No correlation was found between exhaled NO levels and CT-assessed disease extent.
- Pulmonary function impairment did not correlate with exhaled NO levels.
Conclusions:
- Exhaled nitric oxide levels are not increased in pulmonary sarcoidosis.
- NO is not a useful biomarker for detecting or assessing sarcoidosis severity.